Michael M. Matin
Chairman of the Board, CEO
Michael Matin is a co-founder of HDL Therapeutics and is the CEO and the Chair of its Board of Directors. Michael has successfully raised multiple rounds of capital and has led HDL Therapeutics from a single indication device company into a biotechnology and device company with multiple programs in multiple indications. Michael leads the company’s strategic and operational management and has steered the advancement of the HDL Therapeutics’ lead program into the final stage of clinical development currently underway.
Prior to founding HDL Therapeutics, Michael worked for over 20 years in commercial, product development and strategic alliance roles in the pharmaceuticals industry, with over a decade of experience in the cardiovascular field. Michael has led the development of major cardiovascular products through clinical stage development and launch. His last two cardiovascular launches reached peak sales of over $4 billion.
Michael started his life science career at Pfizer where he launched Aricept, a treatment for Alzheimer’s disease. Aricept became a blockbuster and the most successful Alzheimer’s therapy launched to-date. Michael joined Bayer following his tenure at Pfizer. He became responsible for reviving Bayer’s portfolio of cardiovascular products. Under his leadership, Bayer’s portfolio of cardiovascular products grew to $1 billion through expanded labeling, repositioning and re-launching major brands. Michael joined Schering-Plough to lead its portfolio of cardiovascular products through clinical development into launch. He helped build a $4 billion cardiovascular franchise at Schering-Plough.
Michael received his B.S.F.S. from the School of Foreign Service at Georgetown University and his MBA from Columbia University.
H. Bryan Brewer, MD
Chief Scientific Officer
Bryan is a co-founder of HDL Therapeutics, and is the Chief Scientific Officer of the company. He leads the clinical development program of the company. Bryan was previously a member of the Board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States, and has served on the editorial boards of several prestigious journals including Clinical Lipidology. Bryan’s research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinias. He has pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis. Bryan has published more than 450 original manuscripts and 75 reviews and book chapters on the subjects of genetic dyslipoprotenias, lipoprotein metabolism, and atherosclerosis.
Bryan is a recipient of the JD Lane Investigator Award from the US Public Health Service, the Heinrich Wieland Prize from the Federal Republic of Germany and the Public Health Service Commendation Award, Meritorious & Service, Distinguished Service Medals from the NIH, George Lyman Duff Memorial Award Lecture, and the Robert I. Levy Award.
Prior to co-founding HDL Therapeutics, Bryan was a Director, Washington Cardiovascular Associates, Senior Research Consultant, Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute, a division of MedStar Research Institute, and Section Chief of the Molecular Disease Branch at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), a position he held for nearly 30 years.
Bryan received his medical degree from Stanford University School of Medicine. He completed his internship and residency in internal medicine at Massachusetts General Hospital.
D. J. Brignola
Chief Financial Officer
Nick joined our Team from Caris Life Sciences. Nick led the Finance and Revenue Cycle organizations at Caris since 2011. He built the Finance and Accounting operations team at Caris from the ground up, after the Company was spun off as a result of an acquisition. During his tenure at Caris, Nick led the Financial Planning, Accounting, Sales Operations and Treasury functions. During his last year at Caris, Nick was charged with helping the Company document processes and assess its internal control structure, as well as assisting the Company in its efforts to raise additional capital. Nick began his life science career at Schering-Plough as an auditor and held financial positions with increasing responsibilities in Manufacturing, Accounting, Finance, and Compliance. His last role at Schering-Plough was Finance Director in the Global Cardiovascular Franchise a $ 4 billion business at its peak. Nick was responsible for all aspects of planning and reporting for Schering’s portfolio of cardiovascular products in clinical development through commercialization. After Schering-Plough, Nick led the Commercial and Research Finance organizations at Shionogi, also serving as a Board Director and Treasurer for Shionogi Pharma. While at Shionogi, he helped re-build some of Shionogi’s accounting and governance processes, as well strengthened the Company’s Medicaid Drug Rebate program.
Nick received his B.S. in Business Logistics from The Pennsylvania State University and his MBA from Louisiana State University. Nick is also a Certified Internal Auditor and has earned professional certifications in Occupational Safety and Transportation and Logistics.
Timothy J. Perlman
VP, Systems Development & Clinical Operations
Tim is a member of HDL Therapeutics, Inc. leadership team, and has worked in the biomedical industry for over 20 years. He has a strong background in blood and plasma based new product/process development from concept through launch, and has led high performing teams, partners, and clinical sites to execute the development and implementation of cutting edge medical technologies. He is well versed in the U.S. and International regulatory requirements for medical devices.
Tim led the design and development of HDL Therapeutics’ Plasma Delipidation System, and oversaw the successful completion of the first-in-man clinical feasibility study. Over the course of his career, he has also been responsible for the development of a number of other blood/plasma processing therapies, including novel lipoprotein modification processes and systems, extracorporeal xenogeneic liver assist systems, and innovative pathogen inactivation processes intended to treat SIV and HIV. Tim has led programs in the diabetes management field, from the design and development of innovative xenogeneic implantable artificial pancreas devices, to next generation integrated blood glucose monitoring systems. Tim has published numerous abstracts and articles in such Journals as the Journal of the American College of Cardiology and the Journal of Lipid Research, and holds over a dozen issued patents in the field.
Tim received his Bachelor of Science in Mechanical Engineering with High Honors from Northeastern University in Boston, and conducted graduate studies in Biomedical Engineering at Worcester Polytechnic Institute in Worcester, Massachusetts.
Nicholas G. Rothwell, CPIM
VP, Global Supply
Nick joined HDL Therapeutics in August of 2015 with more than 30 year’s experience in the life sciences industry. Nick has responsibility for Manufacturing, Supply Chain Management, and Logistics.
Prior to joining HDL Therapeutics, Nick was the EVP of Technical Operations at Archimedes Pharma, a privately held specialty pharmaceutical company with a diverse portfolio of products. He oversaw Archimedes’ global supply functions for the company’s product portfolio. Nick led, the supply functions in support of the launch of the company’s flagship product in the U.S. and in Europe. Nick was a member of the Global Leadership Team and an officer of the company.
Spanning a long career, Nick has held senior level global supply chain positions of increasing responsibility with Novartis, Pharmacia and Wyeth Pharmaceuticals where he contributed to the launch of the largest vaccine in the world.
Nick is a recognized leader in developing, implementing, and effectively managing end–to–end fully integrated supply chains and specializes in improving the overall performance across the supply network and has successfully launched many diverse and complex products over his career.
Nick earned a technical degree in Materials Management while serving in the Royal Air Force and is certified in Production & Inventory Management by APICS, The Association for Operations Management.
Lori A. Carr, RAC, CQA, RABQSA
VP, Quality Management & Regulatory Affairs
Lori has 26 years of experience in the medical device field including Regulatory Compliance, Quality Assurance, Regulatory Affairs, Quality Systems, and Quality System Remediation. Lori is responsible to ensure full compliance of HDL Therapeutics’ manufacturing and established Quality Systems with Federal Regulations.
Lori began her FDA career in 1994 as an FDA Medical Device Registration Monitor and was a member of the FDA Foreign Inspection Cadre for Medical Devices. She conducted domestic and foreign Good Manufacturing Practice (GMP) and Quality System Regulation (QSR) inspections for premarket (including 510(k) and PMAs) and post-market inspections. Lori was an FDA Level II Certified Medical Device Investigator, which is an honor that is bestowed on FDA Investigators that have demonstrated special competence in conducting inspections. Lori has provided training at the FDA National Basic Medical Device School, which trains FDA Medical Device Investigators and industry groups on FDA inspection readiness.
Lori’s Professional Certifications include the Regulatory Affairs Certification (RAC/US) through the Regulatory Affairs Professionals Society (RAPS); Certified Quality Auditor (CQA) through American Society for Quality (ASQ); and RABQSA Principal Auditor (ISO 13485:2003) through Exemplar Global. Lori holds a BS degree in Chemistry from Xavier University in Cincinnati, Ohio.
William J. Hauer
Commercial Field Sales Management
Bill joined HDL Therapeutics in September of 2015 as a field sales management advisor with 30 years experience in the pharmaceuticals industry, leading launch planning, sales force development & management, including 12 years of contract sales leadership. Bill is a two time President’s Club awardee.
Bill began his career with Schering Plough in 1985. He was promoted through the ranks of District Trainer, Hospital Sales Specialist and District Manager, into executive sales management. Bill directed the Key Pharmaceutical field sales organization through the climb of Claritin, K-Dur, Im-Dur, and Vanceril which represented over $1 billion in sales. Bill was promoted to the Director of Managed Markets and subsequently to Marketing Director of Asthma Health Management. Bill was recruited into the contract sales side of the business to help client companies build their sales force capabilities through building high performing contract field sales organization. Bill has crafted the strategy and led the launch of different types of contract sales teams in a broad array of therapeutic areas in medical device, and pharmaceutical industries.
Bill has a Bachelors in Business Administration Degree from the City University of New York.